Daniel Legault

Chief Executive Officer & Director

Dan is an entrepreneur and executive with extensive experience in guiding early stage businesses. As a founder, CEO, and turnaround specialist, he has managed entrepreneurial organizations through key transitions – and recoveries – in the commercial and charitable sectors. In addition to pharmaceuticals, Dan has substantial experience in information technology, marketing analytics, intellectual property governance, and risk management. Dan served as a board member of Green Shield Canada (GSC) for 17 years, one of Canada’s largest health benefits administrators. He is a member of the Law Society of Upper Canada and the New York Bar, and earned his JD at Queen’s University.

Alain Wilson

Chief Financial Officer

Alain is a management consultant with extensive experience in strategy and financial analysis in a variety of industries. Over the last 30 years Alain has worked with senior executives on key strategic issues both in North America and internationally. He was a Vice President and Toronto Office Head for Mercer Management Consulting (now Oliver Wyman), and more recently a founding partner of Revelstoke Partners, a boutique consulting firm focused on assisting mid-market companies. Alain has a Bachelor of Commerce (Honours) from Queen’s University and an MBA from IMD in Switzerland.

John Wallace

Chief Scientific Officer & Director

John is an Adjunct Professor of Physiology & Pharmacology at the Cumming School of Medicine at the University of Calgary. He holds a PhD in Medical Sciences (University of Toronto), a B.Sc. and an M.Sc. in Biological Sciences (Queen’s University). From 2009 to 2012, John was Founding Director of the Farncombe Family Digestive Health Research Institute at McMaster University. He completed post-doctoral studies at the Wellcome Research Laboratories in London, England, and he holds an MBA from the University of Birmingham, England.

David Vaughan

Chief Development Officer

Dave has over 20 years of experience in the pharmaceutical industry as a drug development consultant providing support for preclinical, clinical, regulatory, business development and marketing functions in the anti-infectives, central nervous system and GI disease areas. He is the former head of the anti-infectives product development unit for Bayer Inc. Dave holds a PhD in Clinical Biochemistry from the University of Toronto.

Scott Curtis

VP, Corporate Development

Scott has 6 years of capital markets experience including 3 years as an investment banking professional at Bloom Burton & Co., a leading healthcare-focused investment dealer and advisory firm in Canada. He was most recently Vice President & Research Analyst at Cantor Fitzgerald Canada where he covered a variety of sectors including Specialty Pharma. Scott holds a Bachelor of Biomedical Computing from Queen’s University, a Master of Computer Engineering from the University of Toronto and is a CFA charterholder.